Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation
Author
He, X.
Quek, R. G.
Gogishvili, M.
Gullo, G.
Rietschel, P.
Bondarenko, I.
Sezer, A.
Kilickap, S.
GÜMÜŞ, MAHMUT
ÖZGÜROĞLU, MUSTAFA